Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

By afschroeder • December 1, 2025

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose R, Hurvitz SA, Hortobagyi GN, Slamon DJ, Visco F, Spera G, Zarate JP, Halligan D, Li Z, Loi S. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025 Nov;10(11):105858. doi: 10.1016/j.esmoop.2025.105858. Epub 2025 Oct 17. PMID: 41320342.

Tags: CDK4/6 inhibitor, early breast cancer, Hematology/Oncology, HR positive/HER2 negative, NATALEE, Publications, ribociclib

ASH 2026 Guidelines for Management of Relapsed/Refractory Disease in Adolescents and Young Adults with ALL

O'Dwyer KM, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer JP, Hayes-Lattin[...]

Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm

Pemmaraju N, Marconi G, Montesinos P, Lane AA, Mazzarella L, Sallman DA, Ulrickson ML, Schiller GJ, Erba HP, Wang ES, Walter RB, Deconinck E, Aribi[...]

Tumor suppressor genes, treatments, and survival in US veterans with prostate cancer

Karunanandaa K, Knoche EM, Montgomery RB, Pickett C, Doherty J, Gruber J, Raychaudhuri R, Eaton D, Garraway IP, Rettig M, Maxwell KN, Schoen MW. Tumor[...]